S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

AEON

AEON Biopharma, Inc. ASE · AEON

$0.29 +0.00 (-0.67%)

Deep pullback · -3.81σ Hot zone Grade C

+ Compare Open in Sniper

News · AEON

Full news feed →

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

GlobeNewswire Inc. · 44d ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

GlobeNewswire Inc. · 106d ago

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

GlobeNewswire Inc. · 228d ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Benzinga · 557d ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

GlobeNewswire Inc. · 561d ago

Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Benzinga · 732d ago

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround

Zacks Investment Research · 780d ago

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 800d ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

GlobeNewswire Inc. · 806d ago

Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research · 820d ago

Gold Gains 1%; CXApp Shares Spike Higher

Benzinga · 838d ago

Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results

Benzinga · 838d ago

Dow Falls Over 200 Points; ISM Manufacturing PMI Rises In March

Benzinga · 838d ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

GlobeNewswire Inc. · 840d ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc. · 841d ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

GlobeNewswire Inc. · 851d ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

GlobeNewswire Inc. · 851d ago

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga · 900d ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

GlobeNewswire Inc. · 912d ago

Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday

Benzinga · 1053d ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

GlobeNewswire Inc. · 1054d ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

GlobeNewswire Inc. · 1059d ago

Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2023

Benzinga · 1065d ago

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage

Benzinga · 1742d ago